Valbiotis SAS (ALVAL) - Total Assets
Based on the latest financial reports, Valbiotis SAS (ALVAL) holds total assets worth €19.89 Million EUR (≈ $23.26 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Valbiotis SAS net assets for net asset value and shareholders' equity analysis.
Valbiotis SAS - Total Assets Trend (2015–2024)
This chart illustrates how Valbiotis SAS's total assets have evolved over time, based on quarterly financial data.
Valbiotis SAS - Asset Composition Analysis
Current Asset Composition (December 2024)
Valbiotis SAS's total assets of €19.89 Million consist of 86.1% current assets and 13.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €7.91 Million | 59.1% |
| Accounts Receivable | €2.50 Million | 12.8% |
| Inventory | €2.09 Million | 10.7% |
| Property, Plant & Equipment | €1.47 Million | 7.5% |
| Intangible Assets | €1.11 Million | 5.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Valbiotis SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Valbiotis SAS worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valbiotis SAS's current assets represent 86.1% of total assets in 2024, an increase from 79.6% in 2015.
- Cash Position: Cash and equivalents constituted 59.1% of total assets in 2024, up from 51.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 8.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 59.1% of total assets.
Valbiotis SAS Competitors by Total Assets
Key competitors of Valbiotis SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Orkla ASA
OL:ORK
|
Norway | Nkr88.70 Billion |
|
New Hope Dairy Co Ltd
SHE:002946
|
China | CN¥9.38 Billion |
|
Yankershop Food Co Ltd
SHE:002847
|
China | CN¥4.06 Billion |
|
Bellring Brands LLC
NYSE:BRBR
|
USA | $1.06 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥2.58 Billion |
|
Yantai China Pet Foods Co Ltd
SHE:002891
|
China | CN¥5.36 Billion |
|
Xinjiang Guannong Fruit & Antler Group Co Ltd
SHG:600251
|
China | CN¥5.94 Billion |
|
Xiamen Kingdomway Group Co
SHE:002626
|
China | CN¥8.38 Billion |
Valbiotis SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.43 | 4.89 | 1.70 |
| Quick Ratio | 2.93 | 4.54 | 1.65 |
| Cash Ratio | 1.06 | 0.29 | 0.23 |
| Working Capital | €12.36 Million | €18.68 Million | €5.19 Million |
Valbiotis SAS - Advanced Valuation Insights
This section examines the relationship between Valbiotis SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | -41.1% |
| Total Assets | €19.61 Million |
| Market Capitalization | $25.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values Valbiotis SAS's assets above their book value (1.28x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Valbiotis SAS's assets decreased by 41.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Valbiotis SAS (2015–2024)
The table below shows the annual total assets of Valbiotis SAS from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €19.61 Million ≈ $22.92 Million |
-41.14% |
| 2023-12-31 | €33.31 Million ≈ $38.94 Million |
+22.59% |
| 2022-12-31 | €27.17 Million ≈ $31.77 Million |
-4.59% |
| 2021-12-31 | €28.48 Million ≈ $33.29 Million |
+35.60% |
| 2020-12-31 | €21.00 Million ≈ $24.55 Million |
+39.86% |
| 2019-12-31 | €15.02 Million ≈ $17.55 Million |
+26.11% |
| 2018-12-31 | €11.91 Million ≈ $13.92 Million |
-6.34% |
| 2017-12-31 | €12.71 Million ≈ $14.86 Million |
+682.76% |
| 2016-12-31 | €1.62 Million ≈ $1.90 Million |
+40.12% |
| 2015-12-31 | €1.16 Million ≈ $1.35 Million |
-- |
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more